YOLFTbeta
Sanofi ADR

Sanofi ADR

SNY · NASDAQ · Healthcare / Drug Manufacturers - General

48.37USD-0.09 (-0.19%)

Price History

Full chart

Market Stats

Previous Close48.46
Open48.51
Day Range48.21 – 48.66
52-Week Range39.07 – 49.91
Volume1.68M
Market Cap95.29B
P/E (TTM)20.61
Forward P/E8.59
EPS1.93
Dividend Yield6.18%
Beta0.28
50-Day Avg42.77
200-Day Avg44.71

About

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEOMs. Belen Garijo Lopez M.D.
  • Employees74.85K
  • Headquarters46, avenue de la Grande ArmEe, Paris, France, 75017, USA
  • Websitehttps://www.sanofi.com

Leadership

  • Ms. Belen Garijo Lopez M.D.CEO & Director · b. 1960
  • Mr. François-Xavier RogerExecutive VP & CFO · b. 1962
  • Dr. Michael Quigley Ph.D.Chief Scientific Officer & Head of Research
  • Mr. Thomas Kudsk LarsenHead of Investor Relations & General Medicines · b. 1974
  • Ms. Jamie HaneyExecutive VP & General Counsel
  • Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing · b. 1957
  • Ms. Veronique JailletExecutive VP & Interim Chief People Officer
  • Fabrizio GaudiHead of Austrian, German & Swiss Operations
  • Mr. Erik WallströmHead of Therapeutic Area - Neurology Development
  • Mr. Thomas TriompheExecutive Vice President of Vaccines · b. 1974

Financials

Income Statement

Currency: EUR1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.35B5.96B6.49B7.46B8.03B15.72B28.49B29.49B29.21B28.82B30.75B34.04B35.06B35.96B31.29B32.00B34.86B34.70B36.22B35.68B37.63B37.37B39.17B40.56B41.62B44.29B46.72B
Growth (%)-+11.46%+8.80%+14.91%+7.77%+95.69%+81.23%+3.50%-0.96%-1.34%+6.70%+10.69%+3.00%+2.56%-12.98%+2.26%+8.94%-0.47%+4.40%-1.50%+5.48%-0.70%+4.83%+3.54%+2.61%+6.41%+5.49%
Cost of Revenue1.61B1.44B1.25B1.38B1.43B4.44B7.56B7.59B7.57B7.34B7.88B9.40B10.87B11.10B10.30B10.23B10.92B10.70B11.61B11.44B11.98B12.16B12.26B11.88B12.63B13.21B13.05B
Gross Profit3.74B4.52B5.24B6.08B6.61B11.29B20.93B21.90B21.64B21.48B22.87B24.64B24.19B24.86B20.99B21.77B23.94B24.00B24.61B24.24B25.65B25.21B26.92B28.68B28.99B31.08B33.67B
Gross Margin69.98%75.82%80.69%81.50%82.26%71.79%73.47%74.27%74.08%74.54%74.37%72.39%69.01%69.14%67.08%68.03%68.68%69.16%67.94%67.95%68.17%67.46%68.72%70.71%69.66%70.18%72.07%
Operating Expense2.77B2.94B3.13B3.46B3.54B8.39B16.18B16.17B15.72B17.09B16.50B18.10B18.33B18.43B16.01B15.71B18.32B17.46B18.80B19.57B22.60B11.10B18.79B18.52B22.03B23.83B24.07B
Operating Income971.00M1.58B2.11B2.62B3.07B2.90B4.75B5.73B5.91B4.39B6.37B6.54B5.86B6.43B4.98B6.06B5.62B6.53B5.80B4.68B3.05B14.11B8.13B10.16B6.96B7.25B9.60B
Operating Margin18.15%26.45%32.46%35.09%38.21%18.43%16.67%19.43%20.24%15.25%20.70%19.20%16.72%17.88%15.92%18.95%16.13%18.82%16.02%13.11%8.11%37.77%20.74%25.05%16.72%16.38%20.54%
EBITDA1.21B1.82B2.41B3.00B3.46B5.82B11.67B12.12B10.77B10.48B11.40B11.77B11.55B11.43B10.19B9.54B10.08B9.90B9.64B9.18B10.66B17.53B11.54B13.51B11.39B11.03B12.48B
EBITDA Margin22.56%30.49%37.10%40.19%43.05%37.01%40.95%41.09%36.86%36.37%37.08%34.58%32.96%31.79%32.56%29.80%28.91%28.53%26.61%25.73%28.33%46.90%29.45%33.31%27.37%24.91%26.71%
Net Income625.00M985.00M1.58B1.76B2.07B1.98B2.26B4.01B5.26B3.85B5.26B5.47B5.65B4.89B3.72B4.39B4.29B4.71B8.42B4.31B2.75B12.29B6.22B8.37B5.40B5.56B7.81B
Net Income Margin11.68%16.52%24.43%23.61%25.80%12.62%7.92%13.58%18.02%13.36%17.12%16.06%16.10%13.59%11.88%13.72%12.30%13.57%23.24%12.07%7.32%32.90%15.89%20.64%12.98%12.55%16.72%
R&D911.00M945.00M1.03B1.22B1.31B2.39B4.04B4.43B4.54B4.58B4.58B4.55B4.79B4.91B4.61B4.67B5.08B5.17B5.47B5.89B6.02B5.53B5.69B6.50B6.51B7.39B7.84B
R&D as % of Total Revenue17.03%15.85%15.89%16.35%16.35%15.18%14.18%15.02%15.53%15.88%14.90%13.36%13.66%13.64%14.72%14.58%14.58%14.91%15.11%16.52%16.00%14.80%14.53%16.03%15.64%16.70%16.79%
Interest Expense019.00M321.00M91.49M330.32M151.42M464.70M358.52M278.47M318.82M300.51M391.01M503.29M483.40M457.00M451.83M423.38M399.50M333.43M486.48M536.27M430.84M377.37M384.80M512.82M622.58M626.00M
Interest Expense % of Total Revenue0.00%0.32%4.95%1.23%4.11%0.96%1.63%1.22%0.95%1.11%0.98%1.15%1.44%1.34%1.46%1.41%1.21%1.15%0.92%1.36%1.43%1.15%0.96%0.95%1.23%1.41%1.34%

Balance Sheet

Currency: EUR1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.82B7.84B9.97B9.47B9.73B85.41B86.94B74.27B69.00B71.99B80.05B85.26B100.67B100.41B96.06B97.39B102.32B104.67B99.81B111.41B112.63B114.41B120.24B126.72B126.46B132.80B126.81B
Total Liabilities3.21B3.51B4.18B3.41B3.40B43.88B40.63B28.45B24.28B26.92B31.60B31.98B44.30B42.94B39.02B41.12B44.11B46.95B41.57B52.37B53.40B51.16B51.21B51.57B52.11B54.94B55.09B
Total Equity3.58B4.30B5.77B6.04B6.31B41.06B46.13B45.60B44.54B44.87B48.19B53.10B56.20B57.33B56.90B56.12B58.05B57.55B58.07B59.03B59.23B63.11B68.68B74.78B74.04B77.51B71.38B
Cash202.00M207.00M123.00M143.90M151.66M1.84B1.25B1.15B1.71B540.00M689.00M5.77B1.93B6.38B8.26B7.34B9.15B10.27B10.31B6.92B9.43B13.91B10.10B12.74B8.71B7.44B7.66B
Total Debt461.00M412.00M404.00M416.45M367.64M16.04B11.18B6.94B5.94B6.01B8.83B8.26B15.44B14.53B14.59B14.81B16.55B18.58B15.60B24.70B25.98B23.68B22.41B21.21B18.70B17.91B20.33B
Net Debt259.00M205.00M281.00M272.55M215.98M14.20B9.93B5.79B4.23B5.47B8.14B2.49B13.51B8.15B6.33B7.47B7.41B8.31B5.29B17.71B16.51B9.76B12.32B8.48B9.99B10.46B12.67B

Cash Flow

Currency: EUR1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow828.00M1.20B1.82B1.68B2.26B4.03B6.39B6.60B7.12B8.52B8.52B9.76B9.32B8.17B6.95B7.69B8.92B7.84B7.38B5.55B7.71B7.42B10.52B10.53B10.26B9.08B12.13B
Investing Cash Flow962.00M-389.00M-113.00M-1.41B-349.37M-14.13B-1.10B-790.27M-1.72B-2.15B-7.29B-3.38B-14.70B-1.59B-1.27B-3.46B-3.26B-2.51B639.00M-12.87B-1.21B3.59B-7.30B-2.08B-6.20B-4.41B-2.76B
Financing Cash Flow-238.00M-471.00M-483.00M-1.59B-1.60B9.22B-5.98B-5.85B-4.83B-3.81B-787.00M-4.65B2.89B-4.35B-3.73B-5.18B-3.60B-4.10B-7.90B3.93B-4.19B-6.49B-7.06B-5.82B-8.05B-5.76B-9.26B
Capital Expenditure414.00M372.00M565.00M1.40B370.02M753.17M1.14B1.45B1.61B1.61B1.78B1.57B1.78B1.61B1.40B1.56B2.77B2.08B1.96B1.98B1.79B2.08B2.04B2.20B2.91B3.19B1.99B
Free Cash Flow414.00M827.00M1.25B272.55M1.89B4.03B5.25B5.15B5.50B6.92B6.73B8.19B7.54B6.56B5.56B6.13B6.15B5.75B5.42B3.57B5.93B5.33B8.48B8.32B7.35B5.89B10.14B
Dividends Paid178.00M241.00M323.00M476.49M581.23M734.73M1.61B2.04B2.37B2.71B2.88B3.14B1.37B3.49B3.64B3.68B3.69B3.76B3.71B3.77B3.83B3.94B4.01B4.17B4.45B4.70B5.39B
FCF to OCF50.00%68.97%68.92%16.25%83.64%100.00%82.13%77.98%77.34%81.16%79.04%83.88%80.88%80.27%79.90%79.75%68.92%73.42%73.49%64.36%76.84%71.92%80.58%79.09%71.67%64.82%83.61%
Dividend Paid to FCF43.00%29.14%25.78%174.83%30.73%18.25%30.71%39.65%43.01%39.15%42.76%38.33%18.20%53.16%65.48%59.94%60.08%65.32%68.41%105.69%64.68%73.80%47.27%50.07%60.58%79.92%53.09%

Earnings

Report DateMay 13, 2005Aug 31, 2005Nov 8, 2005Feb 24, 2006May 5, 2006Aug 2, 2006Oct 31, 2006Feb 13, 2007May 3, 2007Aug 1, 2007Oct 31, 2007Feb 12, 2008Apr 30, 2008Jul 31, 2008Feb 11, 2009Jul 29, 2009Feb 10, 2010Oct 28, 2010Feb 9, 2011Apr 28, 2011Jul 28, 2011Nov 3, 2011Feb 8, 2012Oct 25, 2012Feb 7, 2013May 2, 2013Aug 1, 2013Feb 5, 2014Feb 5, 2015Apr 30, 2015Jul 30, 2015Oct 29, 2015Feb 9, 2016Apr 29, 2016Jul 29, 2016Oct 28, 2016Feb 8, 2017Apr 28, 2017Jul 31, 2017Nov 2, 2017Feb 7, 2018Apr 27, 2018Jul 31, 2018Oct 31, 2018Feb 7, 2019Apr 26, 2019Jul 29, 2019Oct 31, 2019Feb 6, 2020Apr 24, 2020Jul 29, 2020Oct 29, 2020Feb 5, 2021Apr 28, 2021Jul 29, 2021Oct 30, 2021Feb 4, 2022Apr 28, 2022Jul 28, 2022Oct 28, 2022Feb 3, 2023Apr 27, 2023Jul 28, 2023Oct 27, 2023Feb 1, 2024Apr 25, 2024Jul 25, 2024Oct 25, 2024Jan 30, 2025Apr 24, 2025Jul 30, 2025Oct 24, 2025Jan 29, 2026Apr 23, 2026Jul 30, 2026Oct 30, 2026
EPS Estimate0.650.680.730.630.880.780.710.590.870.890.850.745.425.421.792.032.062.451.782.242.381.212.271.921.541.811.641.851.520.001.470.880.710.770.720.800.670.700.760.961.040.690.721.000.670.770.721.040.690.820.641.031.051.230.751.170.720.920.871.340.911.100.891.370.910.940.861.380.740.951.001.570.851.031.101.63
EPS Actual1.350.730.850.640.971.710.990.661.070.850.990.801.061.040.831.231.011.320.971.231.171.261.031.050.800.800.730.930.790.000.780.880.750.770.730.980.670.770.801.000.650.770.731.040.630.790.731.070.740.880.751.080.730.970.821.280.791.020.881.440.931.190.961.350.900.950.941.540.681.020.911.690.911.101.21-
Surprise107.69%7.35%16.44%1.59%10.23%119.23%39.44%11.86%22.99%-4.49%16.47%8.11%-80.44%-80.81%-53.63%-39.41%-50.97%-46.12%-45.51%-45.09%-50.84%4.13%-54.63%-45.31%-48.05%-55.80%-55.49%-49.73%-48.03%--46.94%0.00%5.63%0.00%1.39%22.50%0.00%10.00%5.26%4.17%-37.50%11.59%1.39%4.00%-5.97%2.60%1.39%2.88%7.25%7.32%17.19%4.85%-30.48%-21.14%9.33%9.40%9.72%10.87%1.15%7.46%2.20%8.18%7.87%-1.46%-1.10%1.06%9.30%11.59%-8.11%7.37%-9.00%7.64%7.06%6.80%10.00%-
TimingPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hours-Pre-market-Pre-market-Pre-marketPre-marketPre-marketPre-market-Pre-market-Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap95.29B
Enterprise Value121.92B
Trailing P/E20.61
Forward P/E8.59
PEG Ratio28.63
Price / Sales1.95
Price / Book1.28
EPS1.93
Book Value32.35
Revenue (TTM)48.92B
Gross Profit (TTM)35.93B
EBITDA13.54B
Profit Margin8.09%
Operating Margin21.03%
Return on Equity5.71%
Return on Assets5.09%
Shares Outstanding2.40B
Shares Float2.16B
Beta0.28
Dividend Yield6.18%
Dividend Rate2.42
Payout Ratio49.33%

Analyst Ratings

Buy
Based on 10 analystsTarget 53.61
  • Strong Buy
    5
  • Hold
    5

Ownership Breakdown

Institutions
8.01%
Insiders
0.00%
Retail / Other
91.99%

Top Institutional Holders

  • Dodge & Cox
    28.09M1.17%
  • Morgan Stanley - Brokerage Accounts
    10.70M0.45%
  • Fisher Asset Management, LLC
    10.63M0.44%
  • Bank of America Corp
    8.01M0.33%
  • Amvescap Plc.
    6.80M0.28%
  • JPMorgan Chase & Co
    6.57M0.27%
  • Mondrian Investment Partners Ltd
    5.52M0.23%
  • Brandes Investment Partners & Co
    4.14M0.17%
  • Federated Hermes Inc
    3.85M0.16%
  • Boston Partners Global Investors, Inc
    3.84M0.16%
  • Millennium Management LLC
    3.73M0.16%
  • FMR Inc
    3.68M0.15%
  • Wells Fargo & Co
    3.27M0.14%
  • Royal Bank of Canada
    3.17M0.13%
  • The Goldman Sachs Group Inc
    2.99M0.13%
  • Barclays PLC
    2.68M0.11%
  • Barrow Hanley Mewhinney & Strauss LLC
    2.68M0.11%
  • VGI Partners Ltd
    2.65M0.11%

Top Fund Holders

  • Dodge & Cox Stock I
    20.90M0.87%
  • Invesco Comstock A
    4.03M0.17%

Dividends

20261×
2.42May 4, 2026
20251×
2.21May 9, 2025
20241×
2.04May 9, 2024
20231×
1.90May 30, 2023
20222×
0.30May 26, 20221.75May 4, 2022
20211×
1.91May 3, 2021
20201×
1.75Apr 30, 2020
20191×
1.74May 7, 2019
20181×
1.86May 9, 2018
20171×
1.58May 11, 2017
20161×
1.63May 5, 2016
20151×
1.62May 6, 2015
20141×
1.91May 7, 2014
20131×
1.86May 6, 2013
20121×
1.76May 7, 2012
20111×
1.82May 11, 2011
20101×
1.63May 17, 2010
20091×
1.42Apr 20, 2009
20081×
1.51May 16, 2008
20071×
1.15Jun 4, 2007
20061×
0.91Jun 2, 2006
20051×
0.80Jun 2, 2005
20041×
0.03Sep 27, 2004

Stock Splits

  • Sep 30, 20135:1
  • Nov 17, 201010:1